PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 20260 citationsOpen Access

Pharmacovigilance and Herbal Medicine Safety: A Comprihensive Review

View Full Paper
NSNeelam Thakur*, Harsh Thakur, Kavita Pathania, Pooja Sharma

Key Points

  • This review examines the need for dedicated pharmacovigilance for herbal medicines and highlights potential safety risks.
  • Analyzed global monitoring systems for herbal safety, focusing on WHO's Programme for International Drug Monitoring and VigiBase.
  • Discussed regulatory frameworks, particularly the EU’s THMPD and the US’s DSHEA.
  • Evaluated the limitations of existing causality tools for multi-compound botanicals.
  • Identified chronic underreporting and regulatory loopholes as significant barriers to herbal safety.
  • Emphasized the importance of technology-driven approaches, like AI-based signal detection and molecular fingerprinting.
  • Advocated for improved global regulation and enhanced communication between healthcare providers and patients.

Abstract

Background: Pharmacovigilance (PV) used to deal mostly with synthetic drugs, yet now it also covers herbal medicines because their use keeps growing worldwide. A lot of people still think “natural automatically equals safe,” and that idea is genuinely risky. Herbal treatments are not fully safe. They may contain complex chemicals that can cause serious adverse drug reactions (ADRs), even severe organ toxicity. Objective: This review looks at the urgent need for dedicated herbal pharmacovigilance, using Papaver somniferum (the opium poppy) as the main clinical example to show the real pharmacological strength, narrow therapeutic range, and serious herb-drug interactions (HDIs) found in plant-based medicines. Scope of Review: The study looks at global systems used to monitor herbal safety, with close attention to the WHO Programme for International Drug Monitoring, VigiBase, and the Indian Pharmacopoeia. It also examines why standard causality tools like the WHO-UMC scale often do not fit multi-compound botanicals very well. Then it compares uneven regulations, especially the European Union’s THMPD and the United States’ DSHEA. Key Findings: The assessment points to chronic underreporting, natural chemical variability, and some pretty serious regulatory loopholes as the main obstacles to botanical safety. Even so, the field is moving into “Vigilance 2.0.” This shift leaves passive reporting behind and leans on technology-driven surveillance, using molecular fingerprinting, AI-based signal detection, social listening, and pharmacogenomics to catch hidden toxicities and prevent dangerous synergistic interactions. In conclusion: bringing herbal medicine into modern healthcare needs strict and shared scientific oversight. Current problems won't be solved without better global regulation, the use of Real-World Evidence (RWE), and more honest communication between clinicians and patients. In the end, stronger pharmacovigilance is what makes traditional botanicals safer without putting public health at risk.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Neelam Thakur*, Harsh Thakur, Kavita Pathania, Pooja Sharma (2026) studied this question.

synapsesocial.com/papers/6a1d22bb02fbce9130638739https://doi.org/10.5281/zenodo.20454769
Ask AI
Helpful
Bookmark
Share
View Full Paper